Arca
Skip to content

SV2A: Synaptic vesicle glycoprotein 2A

A drug works by acting on something in the body, usually a protein made by one gene. This is a page for each of those targets: the drugs that hit it and the diseases it is tied to.

Plays a role in the control of regulated secretion in neural and endocrine cells, enhancing selectively low-frequency neurotransmission.

  • Drugs that act on it: 3
  • With a US drug page: 2
  • Type: Protein

Drugs That Act on It

Approved and clinical-stage drugs ChEMBL records for this target; those with a US approval link to their page
BrivaracetamApprovedSynaptic vesicle glycoprotein 2A modulatorModulator—
LevetiracetamApprovedSynaptic vesicle glycoprotein 2A modulatorModulator—
Seletracetam—Synaptic vesicle glycoprotein 2A modulatorModulator—

Diseases Most Associated With It

Open Targets association score, 0 to 1; all associations
Seizure
0.61
Bilateral tonic-clonic seizure
0.60
Botulism
0.58
Neurodegenerative disease
0.55
Developmental and epileptic encephalopathy 113
0.48
Abnormality of the skeletal system
0.45
Focal-onset seizure
0.41
Focal impaired awareness seizure
0.37

Genes and Related Targets

Complexes and families that share a gene with this target
Genes
SV2A

Drugs and mechanisms are from ChEMBL CHEMBL1998 (CC BY-SA 3.0). Gene name, function (UniProt Q7L0J3, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.